

# CITATION REPORT

List of articles citing

**Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function**

**DOI: 10.1111/liv.13102**

**Liver International, 2016, 36, 807-16.**

**Source:** <https://exaly.com/paper-pdf/65285889/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
247	Anti-hepatitis C virus drugs and kidney. <i>World Journal of Hepatology</i> , <b>2016</b> , 8, 1343-1353	3.4	12
246	Hepatitis C Therapy in Renal Patients: Who, How, When?. <b>2016</b> , 5, 313-27		9
245	The quest for safe and effective treatments of chronic hepatitis C in patients with kidney impairment. <i>Liver International</i> , <b>2016</b> , 36, 791-3	7.9	11
244	Treatment of chronic hepatitis C virus infection in patients with end-stage renal disease on hemodialysis. <b>2016</b> , 8, 76-78		
243	Effect of Hepatitis C Positivity on Survival in Adult Patients Undergoing Heart Transplantation (from the United Network for Organ Sharing Database). <b>2016</b> , 118, 132-7		21
242	Hepatitis C Virus Infection in Chronic Kidney Disease. <b>2016</b> , 27, 2238-46		61
241	Finally, safe and effective treatment options for hepatitis C in hemodialysis patients. <b>2016</b> , 65, 7-10		12
240	Treatment of hepatitis C in renal impairment and renal transplant. <b>2016</b> , 8, 438-448		
239	Direct-acting antivirals for the treatment of chronic hepatitis C in patients with chronic kidney disease. <b>2016</b> , 9, 887-897		11
238	Reply to: "Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease". <b>2016</b> , 65, 1065-1066		0
237	Therapeutic drug monitoring for sofosbuvir and daclatasvir in transplant recipients with chronic hepatitis C and advanced renal disease. <b>2016</b> , 65, 1063-1065		6
236	Management of Post-Liver Transplant Recurrence of Hepatitis C. <b>2016</b> , 76, 1711-1717		3
235	Hepatitis C virus infection and chronic kidney disease: Time for reappraisal. <b>2016</b> , 65, S82-S94		65
234	Second generation direct-acting antivirals - Do we expect major improvements?. <b>2016</b> , 65, S130-S142		28
233	Use of direct-acting agents for hepatitis C virus-positive kidney transplant candidates and kidney transplant recipients. <b>2016</b> , 29, 1257-1265		9
232	[Sofosbuvir and daclatasvir combination therapy in hemodialysis patient with liver transplantation]. <b>2016</b> , 12, 536-538		
231	Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure. <b>2017</b> , 32, 2065-2071		37

230	Interferon-free treatment for HCV-infected patients with decompensated cirrhosis. <b>2017</b> , 11, 38-44		13
229	Chronic hepatitis C and chronic kidney disease: Advances, limitations and uncharted territories. <b>2017</b> , 24, 442-453		26
228	Special populations: treating hepatitis C in patients with decompensated cirrhosis and/or advanced renal impairment. <i>Liver International</i> , <b>2017</b> , 37 Suppl 1, 19-25	7.9	12
227	Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4. <b>2017</b> , 45, 267-272		11
226	Treatment of Hepatitis C virus infection in Italy: A consensus report from an expert panel. <b>2017</b> , 49, 731-741		14
225	Direct-acting antivirals: the endgame for hepatitis C?. <b>2017</b> , 24, 31-37		62
224	Hemodialysis Patients Treated for Hepatitis C Using a Sofosbuvir-based Regimen. <b>2017</b> , 2, 831-835		24
223	Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. <b>2017</b> , 47, 1429-1437		32
222	HCV Antiviral Therapy in Liver Transplant Candidates and Recipients With Renal Insufficiency. <b>2017</b> , 101, 924-932		3
221	The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 46-55	6.1	14
220	International Liver Transplantation Society Consensus Statement on Hepatitis C Management in Liver Transplant Candidates. <b>2017</b> , 101, 945-955		63
219	Successful Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Ledipasvir in Renal Transplant Recipients. <b>2017</b> , 101, 980-986		31
218	Safety and Efficacy of Treatment of Hepatitis C in Kidney Transplant Recipients With Directly Acting Antiviral Agents. <b>2017</b> , 101, 1704-1710		61
217	Elbasvir plus grazoprevir in patients with hepatitis C virus infection and stage 4-5 chronic kidney disease: clinical, virological, and health-related quality-of-life outcomes from a phase 3, multicentre, randomised, double-blind, placebo-controlled trial. <b>2017</b> , 2, 585-594		53
216	Antiviral treatment of hepatitis C in renal transplant patients - safety issues. <b>2017</b> , 16, 873-876		3
215	Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. <b>2017</b> , 1, 248-255		20
214	Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients. <i>Nefrologia</i> , <b>2017</b> , 37, 158-163	0.4	4
213	Transplantation of kidneys from hepatitis C-positive donors into hepatitis C virus-infected recipients followed by early initiation of direct acting antiviral therapy: a single-center retrospective study. <b>2017</b> , 30, 865-873		49

212	Disease Burden, Early Discontinuation, and Healthcare Costs in Hepatitis C Patients with and without Chronic Kidney Disease Treated with Interferon-Free Direct-Acting Antiviral Regimens. <b>2017</b> , 37, 687-697		8
211	Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions. <b>2017</b> , 129, 476-483		13
210	Treating hepatitis C viral infection in patients with chronic kidney disease: When and how. <b>2017</b> , 9, 55-59		1
209	Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis. <b>2017</b> , 36, 113-116		20
208	Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. <b>2017</b> , 66, 718-723		80
207	Effectiveness of direct-acting antivirals in Hepatitis C virus infection in haemodialysis patients. <b>2017</b> , 37, 158-163		7
206	Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis. <i>Liver International</i> , <b>2017</b> , 37, 974-981	7.9	59
205	Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience. <b>2017</b> , 24, 464-471		30
204	Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. <b>2017</b> , 47, 1127-1136		27
203	Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment. <b>2017</b> , 377, 1448-1455		277
202	Treatment of hepatitis C virus in advanced renal disease. <b>2017</b> , 10, 79-81		
201	Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD. <b>2017</b> , 12, 1615-1623		49
200	Transplantation of Kidneys from HCV-Positive Donors: How to Best Use a Scarce Resource. <b>2017</b> , 28, 3139-3141		10
199	Dual Organ Duel: The Hepatorenal Axis. <b>2017</b> , 24, 253-260		2
198	Renal function changes in HCV-infected patients with chronic kidney disease during and after treatment with direct antiviral agents. <b>2017</b> , 49, 1166-1169		2
197	Recurrent Disease Following Liver Transplantation. <b>2017</b> , 1127-1142		
196	Treatment of Extrahepatic Manifestations of Hepatitis C Virus. <b>2017</b> , 21, 631-643		16
195	Comparative treatment effectiveness of direct acting antiviral regimens for hepatitis C: Data from the Veterans administration. <b>2017</b> , 32, 1136-1142		24

194	Prevention of hepatitis C recurrence by bridging sofosbuvir/ribavirin from pre- to post-liver transplant: a real-life strategy. <i>Liver International</i> , <b>2017</b> , 37, 678-683	7.9	9
193	EASL Recommendations on Treatment of Hepatitis C 2016. <b>2017</b> , 66, 153-194		821
192	Direct-acting antivirals for hepatitis C virus in patients on maintenance dialysis. <b>2017</b> , 40, 531-541		9
191	Hepatitis C. <b>2017</b> , 628-698		
190	Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis. <b>2017</b> , 13, 733-738		12
189	Treatment Options in Hepatitis C. <b>2017</b> , 114, 11-21		14
188	Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease. <b>2018</b> , 63, 1334-1340		27
187	Expanding Capacity to Treat Hepatitis C: Overcoming Barriers and New Innovations. <b>2018</b> , 17, 83-87		
186	Generic sofosbuvir-based direct-acting antivirals in hepatitis C virus-infected patients with chronic kidney disease. <i>Liver International</i> , <b>2018</b> , 38, 2137-2148	7.9	23
185	Rationale for treating hepatitis C virus infection in patients with mild to moderate chronic kidney disease. <b>2018</b> , 22 Suppl 1, S97-S103		7
184	Safety of sofosbuvir-based regimens after liver transplantation: longitudinal assessment of renal function in the prospective ANRS CO23 CUPILT study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 1682-1689	6.1	7
183	Efficacy and safety of ledipasvir/sofosbuvir for genotype 1b chronic hepatitis C patients with moderate renal impairment. <b>2018</b> , 12, 133-142		14
182	EASL Recommendations on Treatment of Hepatitis C 2018. <b>2018</b> , 69, 461-511		1079
181	What do clinicians need to watch for with direct-acting antiviral therapy?. <b>2018</b> , 21 Suppl 2, e25076		7
180	End-Stage Renal Disease and Treatment of Hepatitis C Virus Infection. <b>2018</b> , 17, 78-82		1
179	Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. <b>2018</b> , 23, 257-263		12
178	Kidney disease in the setting of HIV infection: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. <b>2018</b> , 93, 545-559		88
177	Managing hepatitis C in patients with the complications of cirrhosis. <i>Liver International</i> , <b>2018</b> , 38 Suppl 1, 14-20	7.9	9

176	Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection. <b>2018</b> , 36, 457	1
175	Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. <b>2018</b> , 48, 529-538	14
174	Efficacy and safety of ombitasvir/paritaprevir/ritonavir combination therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease. <b>2018</b> , 48, 549-555	16
173	Treatment of hepatitis C in special populations. <b>2018</b> , 53, 591-605	20
172	Introduction to hepatitis C virus infection: Overview and history of hepatitis C virus therapies. <b>2018</b> , 22 Suppl 1, S8-S21	19
171	Pharmacokinetics and drug interactions of medications used to treat hepatitis C virus infection in the setting of chronic kidney disease and kidney transplantation. <b>2018</b> , 22 Suppl 1, S22-S35	6
170	Treatment of hepatitis C virus infection in patients with mixed cryoglobulinemic syndrome and cryoglobulinemic glomerulonephritis. <b>2018</b> , 22 Suppl 1, S81-S96	23
169	Rationale for treatment of hepatitis C virus infection in end-stage renal disease patients who are not kidney transplant candidates. <b>2018</b> , 22 Suppl 1, S45-S52	7
168	[Chronic hepatitis C : Standard treatment and remaining challenges]. <b>2018</b> , 59, 528-535	3
167	Real-life experience with direct-acting antiviral agents for hepatitis C virus in end-stage renal disease. <b>2018</b> , 41, 363-370	5
166	Potential nephrotoxicity of sofosbuvir-based treatment in patients infected with hepatitis C virus: a review on incidence, type and risk factors. <b>2018</b> , 11, 525-529	17
165	Treatment Choices for Hepatitis C in Patients with Kidney Disease. <b>2018</b> , 13, 793-795	5
164	Recommendations for the treatment of hepatitis C virus infection in chronic kidney disease: a position statement by the Spanish association of the liver and the kidney. <b>2018</b> , 31, 1-13	11
163	Ledipasvir and Sofosbuvir for untreated HCV genotype 1 infection in end stage renal disease patients: A prospective observational study. <b>2018</b> , 22, 217-221	14
162	Clinical trials: Treatment of HCV-infected patients with advanced kidney disease. <b>2018</b> , 14, 6-8	1
161	Management of Chronic Hepatitis C in End-stage Renal Disease. <b>2018</b> , 52, 287-294	2
160	Sofosbuvir Based Regimen in Management of Hepatitis C for Patients With End Stage Renal Disease on Hemodialysis: A Single Center Experience from India. <b>2018</b> , 8, 116-120	7
159	Decreasing mortality and disease severity in hepatitis C patients awaiting liver transplantation in the United States. <b>2018</b> , 24, 735-743	17

158	Management of hepatitis C in a patient undergoing solid organ (kidney) transplant. <b>2018</b> , 3, 231-237		
157	Successful treatment of genotype 3 hepatitis C infection in a noncirrhotic HIV infected patient on chronic dialysis with the combination of sofosbuvir and velpatasvir: A case report. <b>2018</b> , 97, e13671	0	
156	Expert opinion on the management of renal manifestations of chronic HCV infection. <b>2018</b> , 23, 57-67	2	
155	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). <b>2018</b> , 41, 597-608	10	
154	Guidelines on treatment of hepatitis C virus infection. Spanish Association for the Study of the Liver (AEEH). <b>2018</b> , 41, 597-608		
153	Kidney Function Decline in Patients with CKD and Untreated Hepatitis C Infection. <b>2018</b> , 13, 1471-1478	15	
152	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <b>2018</b> , 13, 1129-1136	2	
151	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <b>2018</b> , 51, 107-113	3	
150	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <b>2018</b> , 50, 1133-1152	2	
149	Autoimmune Kidney Diseases Associated with Chronic Viral Infections. <b>2018</b> , 44, 675-698	4	
148	Association of Renal Function and Direct-Acting Antiviral Agents for HCV: A Network Meta-Analysis. <b>2018</b> , 7,	10	
147	Managing hepatitis C therapy failures and chronic kidney disease. <b>2018</b> , 11, 1135-1142	4	
146	Expert opinion on the management of hepatitis C infection in Kuwait. <b>2018</b> , 10, 117-132	2	
145	KDIGO 2018 Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C in Chronic Kidney Disease. <b>2018</b> , 8, 91-165	95	
144	Incidence of Acute Kidney Injury in Patients Coinfected with HIV and Hepatitis C Virus Receiving Tenofovir Disoproxil Fumarate and Ledipasvir/Sofosbuvir in a Real-World, Urban, Ryan White Clinic. <b>2018</b> , 34, 690-698	5	
143	The Mexican consensus on the treatment of hepatitis C. <b>2018</b> , 83, 275-324	9	
142	Effectiveness, treatment completion and safety of sofosbuvir/ledipasvir and paritaprevir/ritonavir/ombitasvir + dasabuvir in patients with chronic kidney disease: an ERCHIVES study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 35-43	6.1	19
141	Hepatitis B and Hepatitis C Antiviral Agents. <b>2018</b> , 357-380		

140	Population level outcomes and cost-effectiveness of hepatitis C treatment pre- vs postkidney transplantation. <b>2018</b> , 18, 2483-2495		8
139	Hepatitis C Virus Infection in ESKD Patients. <b>2018</b> , 13, 1735-1737		1
138	Hepatitis C virus infection in chronic kidney disease: paradigm shift in management. <i>Korean Journal of Internal Medicine</i> , <b>2018</b> , 33, 670-678	2.5	6
137	Editorial: is sofosbuvir-based therapy suitable for patients with advanced chronic kidney disease?. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 379-380	6.1	1
136	Sofosbuvir plus daclatasvir as an alternative for patients on haemodialysis with genotype 2 hepatitis C virus infection. <b>2018</b> , 36, 457		
135	Preliminary experience with sofosbuvir-based treatment regimens for patients dependent on hemodialysis. <b>2018</b> , 37, 72-73		5
134	Renal safety after one year of sofosbuvir-based therapy for chronic hepatitis C: A Brazilian "real-life" study. <b>2018</b> , 43, 707-713		7
133	Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective. <b>2018</b> , 94, 206-213		12
132	The Mexican consensus on the treatment of hepatitis C. <b>2018</b> , 83, 275-324		
131	Sofosbuvir with NS5A inhibitors in hepatitis C virus infection with severe renal insufficiency. <b>2018</b> , 25, 1501-1506		13
130	Interpretation of the changes in 2018 National Essential Medicine List (NEML) from the specialists. <b>2019</b> , 02, 43-47		1
129	Treatment of Chronic Hepatitis C: Efficacy, Side Effects and Complications. <b>2019</b> , 35, 161-170		31
128	The efficacy of antiviral therapy after renal transplant in a HCV-positive recipient from a HCV-positive donor. <i>Nefrologia</i> , <b>2019</b> , 39, 313-314	0.4	
127	High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents. <b>2019</b> , 51, 2243-2254		4
126	Direct-Acting Antiviral Agents for HCV-Associated Glomerular Disease and the Current Evidence. <b>2019</b> , 8,		14
125	New insights into the rational use of HCV+ organs worldwide. <b>2019</b> , 33, e13739		2
124	Evolution of renal function under direct-acting antivirals treatment for chronic hepatitis C: A real-world experience. <b>2019</b> , 26, 1404-1412		11
123	Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil. <b>2019</b> , 18, 849-854		17



122	Developments in the treatment of HCV genotype 3 infection. <b>2019</b> , 17, 775-785	10
121	Infectious Disease Transmission in Solid Organ Transplantation: Donor Evaluation, Recipient Risk, and Outcomes of Transmission. <b>2019</b> , 5, e416	23
120	Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir With or Without Ribavirin in Patients With Kidney Disease. <b>2019</b> , 4, 245-256	5
119	Treatment of Hepatitis C Virus-Infected Patients with Renal Failure. <b>2019</b> , 97-107	
118	Eradication of HCV Infection with the Direct-Acting Antiviral Therapy in Renal Allograft Recipients. <b>2019</b> , 2019, 4674560	12
117	Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. <b>2019</b> , 71, 660-665	50
116	A liquid chromatography-tandem mass spectrometry method for simultaneous determination of simeprevir, daclatasvir, sofosbuvir, and GS-331007 applied to a retrospective clinical pharmacological study. <b>2019</b> , 1120, 1-7	17
115	Hepatitis C treatment with all-oral direct-acting antivirals: Effectiveness and tolerance in a multicenter, prospective, observational study from French general hospitals (APROVVIE, ANGH). <b>2019</b> , 48, e101-e110	6
114	The efficacy of antiviral therapy after renal transplant in a HCV-positive recipient from a HCV-positive donor. <b>2019</b> , 39, 313-314	
113	Pathophysiology and Treatment of Hepatitis B and C Infections in Patients With End-Stage Renal Disease. <b>2019</b> , 26, 41-50	3
112	Editorial: comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C - authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 117-118	6.1
111	Hepatitis C Virus (HCV) Infection: in Special Situations. <b>2019</b> , 470-489	
110	Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences. <b>2019</b> , 31, 534-539	1
109	Real-World Evidence and Hepatitis C. <b>2019</b> , 411-427	
108	Pharmacokinetics of Daclatasvir, Sofosbuvir, and GS-331007 in a Prospective Cohort of Hepatitis C Virus-Positive Kidney Transplant Recipients. <b>2019</b> , 41, 53-58	3
107	International Liver Transplantation Society Asian Consensus on the Management of Hepatitis C Virus Infection in Resource Limited Setting-From Noncirrhotic to Decompensated Disease and After Liver Transplantation. <b>2019</b> , 103, 733-746	1
106	Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease. <b>2019</b> , 43, 82-87	6
105	Pharmacokinetics and important drug-drug interactions to remember when treating advanced chronic kidney disease patients with hepatitis C direct acting anti-viral therapy. <b>2019</b> , 32, 141-151	3

104	Real life experiences in HCV management in 2018. <b>2019</b> , 17, 117-128	5
103	Direct acting anti-viral medications for hepatitis C: Clinical trials in patients with advanced chronic kidney disease. <b>2019</b> , 32, 135-140	3
102	Treating hepatitis C virus in dialysis patients: How, when, and why?. <b>2019</b> , 32, 152-158	3
101	Direct-acting antiviral agents for liver transplant recipients with recurrent genotype 1 hepatitis C virus infection: Systematic review and meta-analysis. <b>2019</b> , 21, e13047	10
100	Evaluation of histological dynamics, kidney function and diabetes in liver transplant patients after antiviral treatment with direct-acting antivirals: Therapy of HCV-recurrence. <b>2019</b> , 21, e13020	9
99	APASL clinical practice recommendation: how to treat HCV-infected patients with renal impairment?. <b>2019</b> , 13, 103-109	19
98	Management of hepatitis C virus infection in patients with chronic kidney disease: position statement of the joint committee of Italian association for the study of the liver (AISF), Italian society of internal medicine (SIMI), Italian society of infectious and tropical disease (SIMIT) and Italian society of nephrology (SIN). <b>2019</b> , 47, 141-168	
97	Daclatasvir and reduced-dose sofosbuvir: An effective and pangenotypic treatment for hepatitis C in patients with estimated glomerular filtration rate . <b>2019</b> , 24, 316-321	18
96	Direct-acting antiviral therapy slows kidney function decline in patients with Hepatitis C virus infection and chronic kidney disease. <b>2020</b> , 97, 193-201	23
95	Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease. <b>2020</b> , 40, 46-52	2
94	Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. <b>2020</b> , 35, 473-481	4
93	Liver Disease and Chronic Kidney Disease. <b>2020</b> , 863-882	
92	Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study. <b>2020</b> , 52, 190-198	6
91	Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection. <i>Liver International</i> , <b>2020</b> , 40, 1032-1041	7.9 23
90	Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals. <b>2020</b> , 72, 839-846	23
89	Treatment of chronic hepatitis C in patients with chronic kidney disease with Sofosbuvir-based regimens. <b>2020</b> , 24, 25-29	1
88	Sofosbuvir-containing regimens are safe and effective in the treatment of HCV patients with moderate to severe renal impairment. <i>Liver International</i> , <b>2020</b> , 40, 797-805	7.9 11
87	Chronic Hepatitis C Virus Infection After Kidney Transplantation With or Without Direct-Acting Antivirals in a Real-Life Setting: A French Multicenter Experience. <b>2020</b> , 52, 3179-3185	2

86	Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion. <b>2020</b> , 58, 1110-1131		3
85	Effectiveness of direct-acting antivirals in maintenance hemodialysis patients complicated with chronic hepatitis C. <b>2020</b> , 99, e23384		1
84	Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience. <b>2020</b> , 99, e21972		1
83	EASL recommendations on treatment of hepatitis C: Final update of the series. <b>2020</b> , 73, 1170-1218		237
82	Renal function in HCV therapy: Just another thing to ignore?. <i>Liver International</i> , <b>2020</b> , 40, 1018-1020	7.9	2
81	Efficacy and safety of direct-acting antiviral-based treatment in hepatitis C virus infected patients with chronic renal function impairment: An updated systemic review and meta-analysis. <b>2020</b> , 25, 829-838		0
80	Virological and Clinical Outcome of DAA Containing Regimens in a Cohort of Patients in Calabria Region (Southern Italy). <b>2020</b> , 56,		3
79	Direct acting antiviral HCV treatment does not influence renal function. <b>2020</b> , 99, e20436		5
78	Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study. <b>2020</b> , 5, 918-926		9
77	Efficacy and safety of direct-acting antiviral agents for HCV in mild-to-moderate chronic kidney disease. <i>Nefrologia</i> , <b>2020</b> , 40, 46-52	0.4	1
76	Hepatitis c virus and chronic kidney disease. <b>2020</b> , 14, 579-590		5
75	The combination of sofosbuvir and daclatasvir is effective and safe in treating patients with hepatitis C and severe renal impairment. <b>2020</b> , 35, 1590-1594		11
74	2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations. <b>2020</b> , 119, 1135-1157		34
73	KDOQI US Commentary on the 2018 KDIGO Clinical Practice Guideline for the Prevention, Diagnosis, Evaluation, and Treatment of Hepatitis C. <b>2020</b> , 75, 665-683		9
72	Serial changes of renal function after directly acting antivirals treatment for chronic hepatitis C: A 1-year follow-up study after treatment. <i>PLoS ONE</i> , <b>2020</b> , 15, e0231102	3.7	4
71	INASL-ISN Joint Position Statements on Management of Patients with Simultaneous Liver and Kidney Disease. <b>2021</b> , 11, 354-386		1
70	The effectiveness and safety of sofosbuvir-ledipasvir for patients with hepatitis C virus genotype 2 infection. <i>Advances in Digestive Medicine</i> , <b>2021</b> ,	0.1	
69	The effect of anemia on the efficacy and safety of treating chronic hepatitis C infection with direct-acting antivirals in patients with chronic kidney disease. <b>2021</b> , 53, 749-761		2

68	Emerging Management of Hepatitis C in Transplant. <b>2021</b> , 951-969		
67	An updated systematic review and meta-analysis on efficacy of Sofosbuvir in treating hepatitis C-infected patients with advanced chronic kidney disease. <i>PLoS ONE</i> , <b>2021</b> , 16, e0246594	3.7	1
66	Safety and Efficacy of Antiviral Therapy of Chronic Hepatitis C in Chronic Kidney Disease and Hemodialysis Patients. <b>2021</b> , 3, 160-164		
65	Depression in patients with chronic hepatitis-C treated with direct-acting antivirals: A real-world prospective observational study. <b>2021</b> , 282, 126-132		2
64	Sofosbuvir in HCV patients with chronic kidney disease: No time for caution. <i>Liver International</i> , <b>2021</b> , 41, 646-648	7.9	2
63	Updated View on Kidney Transplant from HCV-Infected Donors and DAAs. <b>2021</b> , 13,		4
62	Sofosbuvir-based hepatitis C therapies in patients with chronic and end-stage kidney disease. <b>2021</b> ,		1
61	Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease. <b>2021</b> , 116, 1924-1928		1
60	Curative Therapies for Hepatitis C Virus Infection in Patients with Kidney Disease.. <b>2021</b> , 2, 1316-1325		
59	Management and Treatment of Hepatitis C: Are There Still Unsolved Problems and Unique Populations?. <i>Viruses</i> , <b>2021</b> , 13,	6.2	2
58	Viral hepatitis: Milestones, unresolved issues, and future goals. <i>World Journal of Gastroenterology</i> , <b>2021</b> , 27, 4603-4638	5.6	3
57	Effect of Sofosbuvir/Ledipasvir and Glecaprevir/Pibrentasvir on Serum Creatinine.. <b>2022</b> , 12, 329-335		
56	Histological and biochemical studies on effect of Sofosbuvir (Sovaldi) on adult male albino rat kidney. <b>2021</b> , 45, 286-296		0
55	Neutrophil gelatinase-associated lipocalin partly reflects the dynamic changes of renal function among chronic hepatitis C patients receiving direct-acting antivirals. <i>PLoS ONE</i> , <b>2021</b> , 16, e0256505	3.7	
54	Sofosbuvir-based regimens for HCV in stage 4/5 chronic kidney disease. A systematic review with meta-analysis. <b>2021</b> , 41, 578-589		1
53	Real-life Experience with direct-acting antiviral agents for HCV after kidney transplant. <b>2021</b> , 25, 100337		0
52	Successful treatment of hepatitis C, genotype 3, with sofosbuvir/ledipasvir in decompensated cirrhosis complicated by mixed cryoglobulinaemia. <b>2016</b> , 2016,		6
51	Ribavirin-induced anaemia reduced tacrolimus level in a hepatitis C patient receiving haemodialysis. <b>2018</b> , 2018,		1

50	Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C). <b>2021</b> , 70, 2349-2358		7
49	Sofosbuvir Use in the Setting of End-stage Renal Disease: A Single Center Experience. <i>Journal of Clinical and Translational Hepatology</i> , <b>2017</b> , 5, 23-26	5.2	14
48	Effect of Hepatitis C Treatment on Renal Function in Liver Transplant Patients. <i>Journal of Clinical and Translational Hepatology</i> , <b>2018</b> , 6, 391-395	5.2	1
47	COMBINED NS5A & NS5B NUCLEOTIDE INHIBITOR THERAPY FOR PATIENTS WITH CHRONIC HEPATITIS C WITH STAGE 5 CHRONIC KIDNEY DISEASE ON HEMODIALYSIS. <i>Arquivos De Gastroenterologia</i> , <b>2020</b> , 57, 39-44	1.3	4
46	HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR. <i>Arquivos De Gastroenterologia</i> , <b>2020</b> , 57, 45-49	1.3	5
45	Changes in renal function indices in cirrhotic chronic hepatitis C patients treated with sofosbuvir-containing regimens. <i>Oncotarget</i> , <b>2017</b> , 8, 90916-90924	3.3	3
44	Grazoprevir plus elbasvir and other treatment options in hepatitis C infected patients with stage 4-5 chronic kidney disease. <i>Annals of Translational Medicine</i> , <b>2016</b> , 4, S13	3.2	1
43	KIDNEY DISEASE IN THE SETTING OF HIV INFECTION: CONCLUSIONS FROM A KIDNEY DISEASE: IMPROVING GLOBAL OUTCOMES (KDIGO) CONTROVERSIES CONFERENCE. <i>Nephrology (Saint-Petersburg)</i> , <b>2018</b> , 22, 84-100	0.4	2
42	Efficacy and safety of sofosbuvir-based regimens for treatment in chronic hepatitis C genotype 1 patients with moderately impaired renal function. <i>Clinical and Molecular Hepatology</i> , <b>2017</b> , 23, 316-322	6.9	15
41	Evolution of glomerular filtration rates and neutrophil gelatinase-associated lipocalin during treatment with direct acting antivirals. <i>Clinical and Molecular Hepatology</i> , <b>2018</b> , 24, 151-162	6.9	11
40	Management of hepatitis C viral infection in chronic kidney disease patients on hemodialysis in the era of direct-acting antivirals. <i>Clinical and Molecular Hepatology</i> , <b>2018</b> , 24, 351-357	6.9	0
39	Use of sofosbuvir in chronic kidney disease: Is it necessary?. <i>Clinical and Molecular Hepatology</i> , <b>2017</b> , 23, 308-310	6.9	4
38	Expanding the donor pool: Hepatitis C, hepatitis B and human immunodeficiency virus-positive donors in liver transplantation. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 6799-6812	5.6	9
37	Full-dose sofosbuvir plus low-dose ribavirin for hepatitis C virus genotype 2-infected patients on hemodialysis. <i>Korean Journal of Internal Medicine</i> , <b>2020</b> , 35, 559-565	2.5	3
36	Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease. <i>World Journal of Hepatology</i> , <b>2017</b> , 9, 833-839	3.4	10
35	Hepatitis C and renal transplantation in era of new antiviral agents. <i>World Journal of Transplantation</i> , <b>2018</b> , 8, 84-96	2.3	4
34	Neurocognitive Impairments and Depression and Their Relationship to Hepatitis C Virus Infection.		1
33	Treatment of Hepatitis C Infection with Direct-Acting Antiviral Agents in Liver-Transplant Patients: A Systematic Review and Meta-Analysis. <i>Hepatitis Monthly</i> , <b>2017</b> , 17,	1.8	2

32	Impact of Sofosbuvir-Based Regimens for the Treatment of Hepatitis C After Liver Transplant on Renal Function: Results of a Canadian National Retrospective Study. <i>Experimental and Clinical Transplantation</i> , <b>2019</b> , 17, 59-63	0.8	3
31	Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients. <i>Experimental and Clinical Transplantation</i> , <b>2019</b> , 17, 52-58	0.8	7
30	Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment. <i>Journal of Clinical and Translational Hepatology</i> , <b>2016</b> , 4, 320-327	5.2	14
29	Kidney Transplantation in Cirrhotic Patients. <b>2017</b> , 219-227		
28	The Efficacy and Safety of Sofosbuvir/Ledipasvir Therapy in Patients on Long-term Hemodialysis with Hepatitis C Virus Infection. <i>Indian Journal of Nephrology</i> , <b>2018</b> , 28, 175-176	0.8	
27	Anti-Infective Agents. <b>2019</b> , 15-86		
26	Hepatitis C virus - related cryoglobulinemic vasculitis with renal involvement current possibilities of diagnostic and treatment. <i>Terapevticheskii Arkhiv</i> , <b>2019</b> , 91, 124-130	0.9	
25	Hepatitis C: How Good Are Real-Life Data and Do Generics Work. <i>Gastroenterology Clinics of North America</i> , <b>2020</b> , 49, 279-299	4.4	
24	Emerging clinical pharmacology topics in drug development and precision medicine. <b>2022</b> , 691-708		
23	Emerging Management of Hepatitis C in Transplant. <b>2020</b> , 1-20		
22	The HCV Treatment Revolution Continues: Resistance Considerations, Pangenotypic Efficacy, and Advances in Challenging Populations. <i>Gastroenterology and Hepatology</i> , <b>2016</b> , 12, 1-11	0.7	5
21	Hepatitis C Virus Treatment in Patients With Chronic Kidney Disease and in Kidney Transplant Recipients. <i>Gastroenterology and Hepatology</i> , <b>2018</b> , 14, 280-285	0.7	3
20	Update on the Management of Hepatitis C Virus Infection in the Setting of Chronic Kidney Disease and Kidney Transplantation. <i>Gastroenterology and Hepatology</i> , <b>2018</b> , 14, 687-705	0.7	1
19	Use of sofosbuvir based regimen in patients with end-stage renal disease and chronic hepatitis C; an open label, non-randomized, single arm, single center study from Pakistan. <i>Gastroenterology and Hepatology From Bed To Bench</i> , <b>2020</b> , 13, 141-146	1.2	2
18	Sofosbuvir-based regimens for HCV in stage 4/5 chronic kidney disease. A systematic review with meta-analysis. <i>Nefrologia</i> , <b>2021</b> , 41, 578-589	0.4	
17	Assessment of Renal Function in Egyptian HCV Patients Treated with Combination Therapy of Sofosbuvir and Daclatasvir. <i>Open Access Macedonian Journal of Medical Sciences</i> , <b>2022</b> , 10, 82-86	1	
16	Prevalence and genotype distribution of hepatitis C virus within hemodialysis units in Thailand: role of HCV core antigen in the assessment of viremia.. <i>BMC Infectious Diseases</i> , <b>2022</b> , 22, 79	4	1
15	The Novel Finding of Dynamic Change in eGFR Up to One Year after End of Treatment in HCV-Infected Patients Receiving Sofosbuvir and Velpatasvir.. <i>Viruses</i> , <b>2022</b> , 14,	6.2	1

14	Editorial: clinical impact of sofosbuvir renal toxicity-more light on the way.. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> , 55, 1052-1053	6.1	
13	Sofosbuvir and risk of estimated glomerular filtration rate decline or end-stage renal disease in patients with renal impairment.. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2022</b> ,	6.1	2
12	The Evaluation of the Efficacy and Safety of Patients with Chronic Hepatitis C and Cirrhosis with Polymorphism UGT1A1*28 Treatment with Direct Antiviral Drugs and Ribavirin. <b>2020</b> , 299-312		
11	Estimating the causal effect of treatment with direct-acting antivirals on kidney function among individuals with hepatitis C virus infection.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0268478	3.7	1
10	Breakthroughs in hepatitis C research: from discovery to cure. <i>Nature Reviews Gastroenterology and Hepatology</i> ,	24.2	5
9	Changes in renal function in patients with chronic hepatitis C treated with sofosbuvir-velpatasvir. <i>Advances in Digestive Medicine</i> ,	0.1	1
8	Micro-elimination of hepatitis C in patients with chronic kidney disease: an Egyptian single-center study. <i>The Egyptian Journal of Internal Medicine</i> , <b>2022</b> , 34,	0.5	
7	Association of hepatitis C virus infection status and genotype with kidney disease risk: A population-based cross-sectional study. <i>PLoS ONE</i> , <b>2022</b> , 17, e0271197	3.7	0
6	Utilization of HCV Viremic Kidneys with Genotyping/Subtyping-Free Sofosbuvir/Velpatasvir Treatment Strategy: Experience from China. <b>2022</b> , 2022, 1-8		
5	The world prevalence, associated risk factors and mortality of hepatitis C virus infection in hemodialysis patients: a meta-analysis.		0
4	Effect of gender difference on psychiatric outcomes for hepatitis C virus patients receiving direct-acting antivirals in Egyptian population: a cohort study. <b>2022</b> , 58,		0
3	Factors Associated with Large Renal Function Decline in Patients with Chronic Hepatitis C Successfully Treated with Direct-Acting Antiviral Therapy. <b>2023</b> , 13, 473		0
2	Decade of optimizing therapy with direct-acting antiviral drugs and the changing profile of patients with chronic hepatitis C. 29, 949-966		0
1	Evolution of estimated glomerular filtration rate in HIV/HCV-coinfected patients who received direct-acting antivirals: A multicenter retrospective study. <b>2023</b> ,		0